Category Archives: The Speck

Biotech … Breakdown, Breakout

February 26, 2023 By in $SPSIBI, Biotech, LABD, SPBIO, Speck-Effect, The Speck, Wyckoff

‘The Court Jester’

Court jesters reveal truths like no other.

How appropriate then, that someone who typically plays the ‘village idiot’ comes out with the truth.

Whether the ‘false narrative’ is finally crumbling or not, is not directly related to analyzing price action.

It does, however, provide the backdrop.

The ‘Big Reveal’

The last update in biotech had this to say (emphasis added):

“If this is the big reversal and biotech is the downside leader, unfortunately, that could mean a planned ‘reveal’ by the mainstream media.“

What wasn’t known, was just exactly how the truth would come out. Now, we know.

All of which, brings us to the topic at hand: Biotech SPBIO.

It turns out, SPBIO, is trading most consistently, on a three-day pattern.

Biotech SPBIO, 3-Day

In Wyckoff terms, the market itself defines what timeframes and what support/resistance levels are important.

Next up, we’re going to invert the chart to mimic the price action observed on the leveraged inverse fund LABD.

Biotech SPBIO, 3-Day, Inverted

And now, the characteristics of this sector the market itself, has revealed.

At this juncture, SPBIO, trades in a sequence of 3-Days after which, if there’s a directional move, continues on for nine consecutive bars.

After nine-bars, price action typically enters a correction for an undetermined amount of time.

After the correction’s compete the market has (in the past) continued on a directional move for another nine-bars.

Then & Now

We’re currently in a directional move that’s five ‘3-Day Bars’ in thus far.

If the market adheres to its prior behavior(s), we have at least four more ‘three-days’ to go (not advice, not a recommendation).

Note, the current reversal was identified to the day, with this update:

“However, today’s action is consistent with resolution of the five-months of congestion (not advice, not a recommendation).”

The fact the congestion period for SPBIO has taken so long to (apparently) resolve itself, has produced the potential for price action to go farther, last longer than anyone would normally expect.

That move if it happens, connects well with the introduction at the top of this post; a large part of the public has been informed in no uncertain terms, it was all a lie.

The needle, and the damage done.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Moderna … Options Strategy

February 19, 2023 By in Biotech, Dr. Elder, MRNA, The Speck, Wyckoff, ZeroHedge 1 Comment

Trend Contact … Then, Pivot Down

With a potential right-side trend (and channel) contact confirmed; shown below at – 86% annualized, odds are now favorable for a Put strategy.

In addition to the technical factors discussed, listed at the bottom of this post are no fewer than 22-links to the current fundamental state of biotech and their ‘handiwork’.

The weekly chart of MRNA, has a Wyckoff Up-Thrust and a test, confirmed by the downside pivot.

Moderna MRNA, Weekly

Notice the reversal action took place at a very weak Fibonacci 23.6% retrace.

The two blue lines on the daily chart (below) are exactly parallel.

The grey lines are parallel to the blue lines and intended to show MRNA, exhibits a repeating (downtrend) pattern.

Moderna MRNA, Daily

The expanded version on the daily has support being penetrated (horizontal blue line) and then ‘spring’ action last Friday as a result.

Of course, it’s ‘what happens next’, that’s the question.

In a prefect scenario, price action would thrust lower for a day or several days and then come back up to test the underside of resistance.

Elder Option Strategy

This strategy is taken from Elder’s book ‘Come Into My Trading Room’, and seeks to use as short-dated options as possible.

Doing so, requires the discipline to wait sufficient amount of time for price action to get into position and for option time value to bleed-off.

Potential Upside

Since we’re already in spring position and price action moved off the lows on Friday, MRNA could continue the upside right back to, or past the downtrend line.

However, with massive (undeniable) fundamentals building buy the day, and MRNA being mentioned specifically in at least one link below, probabilities favor the downside.

Supporting Links For The Bearish Stance

Florida Surgeon General Warns Life-Threatening VAERS Reports Up 4,400 Percent Since COVID-19 Vaccine Rollout

US Says Government, Not Moderna, Should Face COVID-19 Vaccine Lawsuit

New Medical Codes For COVID Vaccination Status Raise Concerns Among Experts

Watch: Rand Paul Grills School Of Nursing Head On Student COVID Vaccine Mandate

US Navy Lifts COVID Vaccine Mandate For Sailor Deployment

Mainstream Media Continues To Push False ‘COVID Heart’ Narrative To Explain Excess Deaths

NFL Players’ Association Urged To Screen for Heart Issues Over Vaccine Side Effects

WHO Suddenly Shelves Plans For Second Phase Investigation Into Origins Of COVID-19: Report

Watch: CDC Director Suggests It Will Never Change Child-Masking Policy

Rand Paul Introduces Bill To Halt Funding For Hospitals Denying Care To The Unvaxxed

Welfare State Weakens… 30 Million Americans Are About To Lose ‘COVID’ Food Stamp Handouts

IMF Says World Needs To Prepare For The “Unthinkable” After COVID, War In Ukraine

COVID Emergency, Climate Emergency: Same Thing

Novavax To Sell US Government 1.5 Million More Doses Of COVID-19 Vaccine

“World’s First” Unvaccinated Dating Service Launches In Hawaii

Living The Lie

‘COVID-Curing’ Sorrento Therapeutics Plunges After Filing For Chapter 11 Bankruptcy Protection

What Can We Learn From The Biggest Lies People Believed About COVID?

Censorship Operations: COVID, War, And More…

CDC Director Defends Mask Mandates After New Study Shows Masking Has Little Effect

Bivalent COVID Vaccines Perform Worse Against Variant Now Dominant In United States: Studies

COVID NEWS COMPILATION WITH NUMBER 33

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Do Not Pass ‘Go’

February 1, 2023 By in 1929, Dow 30, Great Depression, Great Depression 2.0, Greater Depression, IYR, Michael Cowan, Real Estate, Speck-Effect, The Speck, ZeroHedge

Do Not Collect $200

Go Stright To Economic ‘Depression’

And, that’s where we are ladies and gentlemen.

Provided many times on this site, the assessment we’ve gone straight past recession and directly to: ‘The Greater Depression’, or ‘The Great Depression 2.0’

By now, we’re all aware of this data, just out from ZeroHedge.

That data is at the ‘peak’ or the depths of 1932, and we in our current market, haven’t even got started!

‘Entertain Me’

YouTuber, Michael Cowan, has picked up the story.

You can hear the frustration in his voice (time stamp 1:31) as everybody seems to be waiting to be ‘entertained’ with a crash before they do anything.

It’s a good thing we’re not part of that ‘crowd’, right? 🙂

Lions and Tigers and The Fed, Oh My!

The Fed’s interest rate announcement is due out at 2:00 p.m., Eastern, today; does it really matter?

We can see with unbiased observation; the wheels have already, irrevocably, been set in motion.

The economy along with the ‘elephant’ that no one talks about, are juggernauts on a downward course.

The 1929 Crash, Then Bull Rally

Remember, the big market speculators of the early 1900s typically made their fortunes on the way down (not advice, not a recommendation).

Let’s also not forget, one of, if not the largest market rallies up to that time (in percentage terms), happened right in the middle of The Great Depression.

Chart by macrotrends: www.macrotrends.net

Of course, to trade that mid-1930s rally, you had to have the capital to do so.

Which brings us to the next topic: Real Estate.

Real Estate IYR, Weekly

With yesterday’s new print high, we’re at Fibonacci Week 34. That puts us at a potential trading channel or inflection point as discussed in this post.

There’s no guarantee of a trading channel or even a reversal.

However, we do have a confluence of events; upside volume (pressure) declining, marginal new highs and the potential Fed pivot point, due out today.

It’s about 20-minutes before the open. Let’s see what happens next.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Oil … Gas … Gold & Newmont

January 21, 2023 By in Dow 30, GDX, GLD, GOLD, Gold & Silver, Gold Miners, Inflation, IYR, Michael Cowan, NEM, Oil & Gas, Prechter, QQQ, S&P, S&P 500, Speck-Effect, SPY, The Speck, Twitter, XOM, ZeroHedge 1 Comment

Markets, At Critical Juncture

Nemont Mining (NEM), Gold, and the Oil & Gas Sector are at a critical juncture.

The rest of the major indices, Dow, S&P, QQQs, real estate (IYR), and so on, are in a similar position.

For this update, we’ll focus on Newmont (NEM), as it’s the largest cap in the Senior Mining Sector GDX, and a general representative of the commodities markets.

Financial collapse is a process, not an event.

Newmont topped-out in April, of last year. Exxon, the proxy for the Oil & Gas sector, may have reached its highs this past November.

Where’s The Inflation?

As Michael Cowan has just reported, banks are absconding with depositor’s money under the guise of ‘bail-in’.

If the fiat cash is so worthless, why are banks seizing it?

As Robert Prechter Jr., said years ago, ‘all fiat cash ultimately goes to zero’; the end game (most likely) for the dollar. However, it could be months, years, or even a decade before that happens.

For right now, today, this minute, the data is showing us, the banks want the money; ‘Show me the money‘.

With that, let’s look at the non-existent ‘inflation’ in the mining sector.

Newmont Mining NEM, Weekly

The first chart identifies the heavy volume and then test of wide price bars. This behavior is common in the markets; they tend to come back and test wide high-volume areas.

Next, we see there’s a terminating wedge developing as volume declines; the inference, is lack of significant commitment at these price levels.

We’ll get close-in on the wedge; last week printed a lower weekly low and closed lower for the week.

There’s no breakdown of the wedge … yet.

At this juncture, it’s up to the bulls to show they’re still in control.

Inflation vs. Scarcity

We have without a doubt, the effects of the event from the past three years gaining momentum. Whether or not those effects reach a peak this year, is unknown.

A lot of the mainstream and YouTuber’s alike talk about the upward move in gold as the result of ‘inflation’.

Here’s a little bit of insight you’ll not find anywhere else; how about gold rising because the above mentioned ‘effects‘ are causing production volumes to decline?

Maybe it’s because of scarcity (along with nearly everything else) that’s causing the increase in price.

Just to drive that idea home, the latest total gold production numbers, listed here.

Gold production for 2020 dropped -8.2%, from the year prior. Year 2021 was down -1%, from 2020.

From 2010 to 1019, gold production increased or was flat year over year … that is, until 2020.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Precious Metals … Silver & Gold

January 15, 2023 By in GLD, Mannarino, Palladium, Platinum, SLV, Speck-Effect, The Speck, ZeroHedge 3 Comments

The ‘Non-Confirmation’

Something’s not right in the precious metals sector.

Gold’s just off -8%, from its highs while other monetary metals (Palladium, Platinum, Silver) are far below their highs; silver’s off a whopping -51.75%, from its 2011, highs.

In addition, as we’ll see below, silver (SLV) is just now contacting the right side of a trend line and potential downward channel structure that goes all the way back to the lows of 2015.

The ‘Squeeze’ of 2021

Below on the weekly chart of SLV, is a point labeled “1”.

That’s the location of what turned out to be a right-side trend line contact. Back then, an update on the ‘squeeze’ was posted, linked here.

Taken from that update was the following (emphasis added):

Those attempting garner forces (the little guy) to move the markets, such as silver, will find out soon enough who’s in control … and it’s not them.

It’s unlikely silver is going higher any time soon. There could be some upward spasms as the crowded trade exhausts itself; it’s likely we’ve seen the SLV highs for quite some time.

So, here we are nearly two years later; SLV never posted higher than the February 2nd, squeeze of 2021.

So, what’s next? Is there something else going on?

We’ll look at that question after the charts.

Silver SLV, Weekly

First, is the un-marked chart.

Next, we see a pattern that’s not so clear without mark-up.

For SLV, to break out, there needs to be an absence of motivated sellers (prices drift higher) or sufficient buying demand to overcome the downward trend.

Inflection Point

For an idea of what’s likely to happen next, we’re going to go to an unlikely source; Daniela Cambone and Gregory Mannarino.

It’s not about ‘controlling’ inflation and it never was, going all the way back to 1913. It’s about the ‘end game’, as discussed by Mannarino.

“Eliminate The Middle Class” (time stamp 11:40)

The sticky wicket is the ‘debt bubble’ and the ‘elephant’.

The Elephant Grows

The chart of silver (and other precious metals) and its non-confirmation with gold, could be an indicator of debt collapse and demand collapse first, before hyperinflation.

Multiple times a day now we have reports like the following flooding into the marketplace:

COVID Vaccines Are “Obviously Dangerous” And Should Be Halted Immediately, Say Senior Swedish Doctors

‘Normalization’ Of Emergency Use Authorizations Concerns Health Experts

CDC Says Stroke Concerns Over Pfizer Jab Warrant Investigation

They Promised “Safe And Effective”; We Got “Sudden And Unexpected”

Pentagon “Exploring” Back-Pay For Troops Kicked Out Over COVID Vaccine Mandate

Multiple Young Athletes And Former Athletes Died Suddenly This Past Month

Doctor Calls For Withdrawal Of Pfizer, Moderna COVID-19 Vaccines Following New Research

The above list is just since yesterday and it’s only 2:00 p.m., Central Time, today!!!

Monetary & Manufacturing

Silver is unique more so than gold, in that it’s an industrial metal as well as monetary.

The collapse in manufacturing demand could be the reason silver’s not confirming gold’s move.

It may also be telling us, as the effects of the elephant take hold, a huge liquidation of all assets could be coming; paradoxically as the need for fiat cash (not precious metals) to pay off debt, increases.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … Breakout or Breakdown

January 13, 2023 By in $SPSIBI, Biotech, LABD, SPBIO, Speck-Effect, The Speck, Usual Suspects, Wyckoff, ZeroHedge 1 Comment

The Usual Suspects

During the past three months, biotech index SPBIO, has been oscillating, coiling like a spring; preparing for a dramatic move.

Then yesterday (Thursday), there’s an upside launch.

We now have price action instability; either the bulls or the bears are in control.

At this point, we don’t know who has the upper hand.

However, based on the list of recent news items below, it does not look good for the bulls.

Biotech’s Frankenstein

Within the past few days, we have this:

Deadline Passes For Pfizer To Submit Results Of Post-Vaccination Heart Inflammation Study To US Regulators

FDA Deviated From Normal Process In Pfizer Vaccine Approval, Documents Show

Former Employees Sue ESPN After Being Fired For COVID Vaccine Refusal

Lead Author Of Research On Pfizer And Moderna Trials Warns COVID Vaccinations Must Be Stopped

Pentagon Drops COVID-19 Vaccine Mandate For Troops

Let’s see if the market’s ready to hand it to this sector. What’s the price action telling us.

Biotech SPBIO, Weekly

The weekly chart shows the potetial breakout.

However, since we’re looking at this from a ‘going short’ perspective (not advice, not a recommendation), the chart following this one is inverted.

When we invert the chart, it takes on a whole different look.

Biotech SPBIO, Weekly (Inverted)

If price action’s spent over three months getting where support has been penetrated only to have it fail into a reversal, the ensuing move has massive potential.

In Wyckoff terms, it’s cause and effect.

The ’cause’ has been three months of congestion. The ‘effect’ is a potential long duration, or wide volatility move.

Before The Open

It’s twenty minutes before the open and 3X leveraged inverse fund LABD, is trading higher by about +3.5%.

This is normal behavior whether we have a reversal or not.

One last check of ZeroHedge, before releasing this post turns up this:

Senator Questions CDC On Why It Claimed No ‘Unexpected Safety Signals’ For COVID Vaccines

The ‘monster’ continues to grow.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Claus & Effect, The Next Wave

December 24, 2022 By in $SPSIBI, Biotech, Catherine Austin Fitts, CVNA, NFLX, SPBIO, Speck-Effect, TGT, The Speck, Useful Idiots, ZeroHedge 1 Comment

Unprecedented … Again

Nefarious forces operate in distraction and darkness.

“And this is the condemnation, that light is come into the world, and men loved darkness rather than light, because their deeds were evil.”

The year 2021, was the year everyone (except children) showed their true colors; they made their decision, knowingly or not, for darkness or light.

This year, 2022, is where the effects (or ‘side effects’) of that decision began to take hold.

Now, as 2023 approaches, we’re likely to move into the realm of unprecedented chaos and collapse.

As if on cue, under the cloak of this week’s holiday distraction, we have what’s possibly the next wave.

This could be the reason as presented in the last update, why biotech appears to be in the early stages of disconnecting from the overall market.

That separation may continue or not; price action is always the final arbiter.

The ‘Woke’ Go Broke

The useful idiots that comprise the ‘woke’ business crowd may be in for the biggest surprise in the coming year.

If there is one overriding theme to keep in mind for 2023, this could be it.

Separate enclaves are now forming of those who have not, will not, and are not going to go along with the ever more unbelievable narratives.

Here is a link to just one of those enclaves.

As a digression; in Texas, we’re just now coming out of yet another record-breaking cold spell.

That’s two, never before seen record breaking low temp events within the past three years!

How does that fit with the global warming narrative?

Anyone awake knows full well what’s going on … and it’s not global warming.

Who’s On First: NFLX or TGT?

Now that vending machine Carvana (CVNA), is out of the way, who’s next?

Partly as a result of economic decline and partly from the decision to take consumer spending elsewhere, Netflix and Target now appear ready to continue their implosion.

More on their technical chart conditions in the next update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech Disconnects & The Claus

December 23, 2022 By in $SPSIBI, Biotech, IWM, LABD, Positions, Russell 2000, SPBIO, Speck-Effect, The Speck, TZA, TZA-22-02, Vernon Coleman, Wyckoff, ZeroHedge 1 Comment

Naughty or Nice ?

Biotech price action’s disconnecting from the rest of the market.

Around the last Fed meeting, biotech separated from the major indices, heading the opposite direction, i.e., sideways to higher.

We’ll see that as we get into the snapshots of the hourly charts (below), but first several clues on why biotech (so far) isn’t going along.

The Next Plan Rolls Out

First up is this, just out on ZeroHedge.

It appears the next push is on … and the target is the kids. Another wave of ‘protection’ is certain to boost profits.

Note: Those commenting on ZH have been ‘awake’ from the start; an invaluable resource.

Next up is this, just out on BrandNewTube; another clear thinker that helps ‘tie it all together’.

Is this the explanation for biotech’s current behavior?

Strictly speaking and from a Wyckoff perspective, we won’t know the real reason for a move until it’s nearing the end.

What we can see, is that character of price action has changed (again).

With that, we’ll look at the 3X, leveraged inverse funds of two indices, Russell 2000 (TZA) and SPBIO (LABD).

TZA & LABD, Hourly

The disconnect has been a recent observation.

We’ll drill right down to the hourly and put the charts one on top of the other.

We can see that while inverse TZA, is now back up to the pre-squeeze high, inverse LABD, is far below that level.

That’s not to say things can’t change quickly.

For now, however, there may be something else going on that’s keeping the sector buoyant and suppressing the LABD, inverse fund.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Pandora & Twitter, The Box Opens

November 29, 2022 By in $SPSIBI, Biotech, LABD, LABD-22-12, Positions, SPBIO, The Speck, Twitter, Van Metre, Wyckoff, ZeroHedge

Fuel, For The Downside

With Twitter’s lifting of the ban on truth, linked here, we may be entering the next phase of collapse.

Whether or not it’s going to immediately show up in market price action, is unknown at this point.

Nascent Reversal?

The last update identified the markets were poised for potential reversal.

Two days later and we’re mostly down; that’s in spite of the supposed positive ‘machine’ bias as presented at this link.

A positive machine-market could still happen (data released tomorrow) but for now, price action itself, is posting lower; this is the crux of Wyckoff analysis … ‘What is the market saying about itself’.

In line with the truth being let out, not surprisingly, chief cook and bottle washer, biotech, is having a rough time.

Biotech Bear Market

Prior posts have documented the bear flag that’s been forming for over nine-weeks. Now, we have an apparent coiled action, ready for the downside.

Since we’re short this sector via LABD (not advice, not a recommendation), we’re going to look at LABD, to identify the potential.

SPBIO, 3X Leveraged Inverse, LABD

We have three charts, all depicting daily action.

The first (un-marked) chart is close-in and it looks like a mess. That is, until you put in trend lines and a Fibonacci count as shown on the second chart.

Adding the mark-up.

Then, keeping those trend lines intact, pulling farther out, we see the potential if there’s a sustained move.

Price action has been trading in a tight range over the past eight-days. Let’s see what happens next.

Positioning

Not advice, not a recommendation.

Short position in SPBIO via LABD; details are as follows:

LABD-22-12:

Entry @ 19.9194, 20.91***: Stop @ 19.28***

Note: Positions may be increased, decreased, entered, or exited at any time.

***, Indicates change

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Set For ‘Implosion’ … Biotech

November 24, 2022 By in $SPSIBI, AMGN, BEAM, Biotech, FATE, GILD, LABD, LABD-22-10, Positions, SPBIO, The Speck, TWST, VRTX, Wyckoff, ZeroHedge 2 Comments

IBB & SPBIO, at The Danger Point®

Each one in their own way, as we’ll see below.

From a Wyckoff standpoint, we’ve identified one of, if not the sector(s) most likely to decline the farthest and fastest in a bear market.

Without question, biotech contains the overriding ‘elephant’ that’s literally affecting everything else on the planet (not advice, not a recommendation).

As stated in the tag-line above, the two indices in question are IBB (large cap) and SPBIO (small cap).

IBB, has Amgen, Gilead and Vertex, as the top three while SPBIO, has more speculative (i.e., losing more money) Beam, Twist and Fate.

Index IBB has $342.8-Bil, combined for the top three while SPBIO has only $6.5-Bil, combined.

So, it makes sense the more speculative ‘cash burning inferno‘ TWST, is in the SPBIO. 🙂

On to the charts

IBB Weekly

IBB has formed a decisive resistance area as shown.

The fourth attempt which pushed above the prior three levels (and retraced), puts IBB, at The Danger Point®

Next up is the SPBIO.

It’s much weaker and thus the focus for any short opportunities (not advice, not a recommendation).

SPBIO ($SPSIBI), Weekly

While IBB, has moved higher, to an up-thrust over the past nine weeks, SPBIO during that time, has languished.

Note: The chart scales are identical. Scrolling up and down, one can visually see the weakness of SPBIO.

SPBIO, also reached all-time highs, six months before IBB.

Getting Closer-In: SPBIO

We’re going to look at the hourly chart.

SPBIO, Hourly

Those who are long-time visitors to this site will instantly recognize the set-up: ‘Spring-to-Up-Thrust‘

This Friday, tomorrow, is a shortened trading day.

There’s a potential we’ll have a small blip higher into the up-thrust zone.

Conversely, for 3X Leveraged Inverse Fund LABD, the potential is for a temporary move lower.

Leveraged Inverse LABD, Hourly

This is how it looks for LABD.

Note for the inverse fund, the ‘spring’ on SPBIO, becomes the ‘up-thrust’ on LABD.

Positioning

Not advice, not a recommendation

Wednesday’s downside action in LABD, resulted in the LABD-22-10, position being stopped out with an overall gain around 7.12%.

There have already been several disruptions to the company’s trading platform and data line over the past month and we’ve not even got started with market chaos.

Recall that just recently, the Canadian market went off-line for several hours. We should consider these events the ‘norm’, on a go-forward basis.

As a result, a standing order (in the market) is in place to go long LABD (short SPBIO) at the execution price of LABD @ 18.62.

That order may or may not be modified as we go into the open tomorrow morning.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279